(Reuters) -Eli Lilly’s international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration’s new fast-track review process, cautioning it was too early to assume the firm would use it for its experimental weight-loss pill orforglipron. “There is very little knowledge about this national priority voucher today. I would not assume we will submit with a national priority voucher, because we do not fully understand what it contains,” Jonsson told Reuters in an interview.

(Reporting by Maggie Fick and Mrinalika Roy. Editing by Mark Potter)

See Full Page